Actually it was strong clinical trial revenue. It was a...

Actually it was strong clinical trial revenue. It was a legitimate contract cancelled through no fault of CDX.
I dont see that as spin except to say, if there is no follow up clinical contracts in the near term it would look more like a one off rather than recurring revenue (through other contracts) It looks like they still have a relationship with clinichain so accept that its good news with money in the bank and lets hope they have a pipeline ready to execute.

That would be a good question for the AGM if anyone is attending. They have mentioned before about strong clinical pipeline I think in the tens of millions, I'd like to know where we are with that.

Other wise, low expenditure and money in the bank, onwards and upwards